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Resumo  
 
Introdução: A Imunodeficiência Comum Variável (IDCV) constitui a causa mais 
frequente de imunodeficiência primária sintomática, caracterizada por 
hipogamaglobulinemia resultante de defeitos na diferenciação das células B periféricas 
e alterações das subpopulações de células T. A sua diversidade imunológica e clínica 
dificultam a investigação da fisiopatologia subjacente e a identificação de factores de 
prognóstico.   
Material e métodos: Foram consultados os processos clínicos e os dados imunológicos 
de 60 doentes adultos (idade média 45 ± 13anos; duração média de follow-up de 8.5 
anos, máximo 24 anos) em 2015. Focou-se posteriormente a análise num subgrupo de 
29 doentes com avaliação clínica e imunológica detalhada em 2008. Além das 
subpopulações de células B, quantificou-se por citometria de fluxo o grau de activação 
das células T e a diminuição das células CD4 naïve e comparou-se com controlos 
saudáveis com idades semelhantes. Compararam-se ainda estes parâmetros em grupos 
IDCV divididos consoante as suas manifestações clínicas. Correlacionaram-se as 
manifestações clínicas e as alterações das subpopulações linfocitárias B e T e avaliou-se 
a estabilidade do fenótipo clínico durante o follow-up. 
Resultados: A prevalência actual de manifestações clínicas não-infecciosas é muito 
elevada, sendo que unicamente 3 doentes apresentam apenas infecções. Não obstante, 
em 63% dos casos, as manifestações iniciais da IDCV foram infecções respiratórias 
recorrentes. Citopénias autoimunes, esplenomegália, adenopatias e proliferação linfóide 
estão associadas a níveis mais elevados de marcadores de activação de células T, perda 
de células T CD4 naïve e expansão de células B CD21
low
CD38
low
. Demonstrou-se que o 
espectro das manifestações clínicas evolui apesar do tratamento de substituição com 
IgG.  
Conclusões: São necessárias terapêuticas adicionais para limitar a progressão de 
complicações não-infecciosas. Actuar sobre as alterações das células T poderá ser uma 
estratégia a ser explorada na terapêutica destes doentes. 
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Abstract 
 
Introduction: Common Variable Immunodeficiency (CVID) represents the most 
frequent cause of symptomatic primary immunodeficiency, defined by 
hypogammaglobulinemia due to defects in peripheral B-cell differentiation and 
disturbances in T-cell subsets. The immunologic and clinical diversity of CVID 
hampers the discovery of underlying disease-causing mechanisms and clinical or 
laboratorial relevant prognostic factors.  
Material and methods: We reviewed medical records and immunological data of 60 
adult patients, (mean age 45 ± 13years; mean length of follow-up 8.5 years, up to 24). 
We further focused our analysis in a subgroup of 29 patients from whom we have 
detailed clinical and immunological evaluations performed 7 years before. In addition to 
the standard B-cell populations, we extended flow-cytometric analysis to quantify the 
loss of naïve CD4 T-cells and degree of T-cell activation. We compared these 
parameters in CVID groups split according to the presence of a given clinical 
manifestation and evaluated the stability of the clinical phenotype, through the analysis 
of the largest adult cohort under follow-up in a portuguese Centre. 
Results: The current prevalence of non-infectious manifestations was remarkably high, 
and an infection-only profile was confined to 3 patients. Nevertheless, in 63% of the 
cases, the initial manifestations were recurrent respiratory infections. Autoimmune 
cytopenias, splenomegaly, adenopathies and lymphoid proliferation were associated 
with significantly higher levels of T-cell activation markers, naïve CD4 T-cell loss and 
expansion of CD21
low
CD38
low 
B-cells. We were able to show that throughout follow-up 
the spectrum of clinical manifestations expands despite IgG replacement treatment.  
Conclusions: Additional therapies are required to contain the emergence of non-
infectious complications that are main determinants of morbidity in CVID patients. Our 
data support that the targeting of T-cell imbalances may be a therapeutic strategy to be 
explored in the management of these patients.  
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Introduction 
 
Common variable immunodeficiency (CVID) represents a heterogeneous subset of 
hypogammaglobulinemias of unknown etiology
1,2
 and the most frequent cause of 
symptomatic primary immunodeficiency
3
. Its frequency is estimated to be 1/25.000-
50.000 in the Western European countries
4,5
. There are regional differences in 
incidence, being a rare diagnosis among Asians and Afro-Americans. There is no 
gender predisposition and the age of onset is usually around the second to third decade, 
although first manifestations of CVID may occur at any age
1,2,6,7
. 
CVID is a primary humoral immunodeficiency disease characterized by quantitative and 
qualitative reduction in antibody production (hypogammaglobulinemia) due to 
heterogeneous defects in mature B-cells and T-cells
4,8
, that should be considered in any 
patient older than 4 years
9
. According to the current diagnostic criteria of the European 
Society for Immunodeficiencies (ESID)
10
, CVID is considered probable in a patient 
who fulfills the following requirements: 
1. At least one of the following: 
a. Increased susceptibility to infection 
b. Autoimmune manifestations 
c. Granulomatous disease 
d. Unexplained polyclonal lymphoproliferation 
e. Affected family member with antibody deficiency 
2. Marked decrease of immunoglobulin (Ig) G and marked decreased of IgA with 
or without low IgM levels (measure at least twice; at least 2 standard deviation 
below the normal levels for the age) 
3. At least one of the following: 
a. poor antibody responses to vaccines (and/or absent isohemagglutinins); 
b. low switched memory B-cells (<70% of age-related normal value) 
4. Secondary causes of hypogammaglobulinemia have been excluded 
5. Diagnosis is established after fourth year of life (but symptoms may be present 
before) 
6. No evidence of profound T-cell deficiency, defined as 2 out of the following:  
a. CD4 counts/μl: 2-6years of life (y) <300, 6-12y <250, >12y <200 
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b. Frequency of naïve CD4: 2-6y <25%, 6-16y <20%, >16y <10% 
c. T-cell proliferation absent 
The range of CVID clinical manifestations is broad, including acute and chronic 
infections, autoimmune and inflammatory diseases and an increased incidence of cancer 
and lymphoma
6
. Therefore, the disease phenotype is both heterogeneous and complex, 
which contributes to an average delay of 6-7 years in the diagnosis of this syndrome
6
. 
As expected, the lack of antibodies which is the main characteristic of CVID, leads to 
recurrent sinopulmonary tract and gastrointestinal infections
1,6
. These infections are 
mainly caused by encapsulated bacteria like Haemophilus influenza, Streptococcus 
pneumonia, as well as Moraxella catarrhalis, different Staphylococci and Giardia 
lamblia
2
. 
Autoimmunity occurs in approximately 10 to 20% of CVID patients and the most 
common autoimmune disease related to CVID is primary immune thrombocytopenia 
(ITP), followed by autoimmune hemolytic anemia (AIHA)
1,3,7
. Other autoimmune 
conditions as antiphospholipid syndrome, diabetes mellitus, inflammatory bowel 
disease, pernicious anemia, rheumatoid arthritis, uveitis, multiple sclerosis, neutropenia, 
primary biliary cirrhosis, systemic lupus erythematosus (SLE), autoimmune thyroid 
disease, vasculitis, psoriasis and vitiligo are also frequently associated with CVID
3,7,11
. 
The inflammatory phenotype in CVID is characterized by polyclonal lymphocyte 
infiltration followed by fibrosis and eventually granuloma formation
7
. Benign 
lymphoproliferation is found in 40 to 50% of the cases, often presenting as 
splenomegaly or lymphadenopathy
1
. In the case of lymphadenopathies, they are usually 
localized in the cervical, mediastinal or abdominal areas. Nevertheless, other tissues 
such as the liver and gastrointestinal tract are also frequently affected. Non-caseating 
granulomas, suggesting sarcoid-like changes
2
, can be found in lymphoid and non-
lymphoid tissues, and are estimated to occur in 8–22% of CVID patients, most 
frequently affecting the lungs, spleen, liver and lymph nodes
1,5–7,12,13
.  
In 10% of CVID patients there is liver disease and abnormal hepatic function tests
1
. 
Nodular regenerative hyperplasia, was reported in 6% of CVID patients and represents 
the most common liver disease in CVID
14
. Seronegative and granulomatous hepatitis 
are other entities found in these patients
1
.  
 From immune phenotype to clinical manifestations in CVID                         Page 7 of 37 
Disturbances in the gastrointestinal tract are present in up to half of CVID patients, 
typically reporting clinical manifestations of diarrhea or malabsorption
7
. Possible 
underlying problems are nodular lymphoid hyperplasia found in 8% of the patients
11
, 
inflammatory bowel disease and higher risk of infection especially by Giardia lamblia, 
followed by Salmonella and Campylobacter jejuni. Moreover, Helicobacter pylori 
infection should also be considered, as it is present in 80% of patients with CVID who 
have dyspepsia
2
. 
Several studies showed that in CVID there is a 1 to 8-fold increase in the risk for overall 
cancer, being lymphoma the most common malignancy with an increased 12-fold risk, 
especially non-Hodgkin B-cell lymphoma, followed by a 10-fold increase in risk for 
stomach cancer, as compared to general population
15
. 
The current overall life expectancy for CVID patients is over 50 years
1
. Interestingly, 
autoimmune conditions, cancers other than lymphoma, history of splenectomy, 
granulomatous disease or the development of bronchiectasis alone have not been 
associated with reduced survival. In contrast, gastrointestinal disease, liver disease, 
lymphoma, chronic lung disease or malabsortion were associated with increased 
mortality
3
. The lower baseline IgG and lower frequency of circulating B-cells were also 
associated with poorer prognosis
1
. Lung involvement, in particular, is the main cause of 
death in CVID patients.
3,7
 
The immunological studies show that most patients have normal or slightly reduced 
numbers of peripheral blood B-cells, very low number of plasma cells in the bone 
marrow, lymph nodes and gut, reduced numbers of memory B-cells (identified by the 
surface expression of CD27) and reduced numbers of isotype-switched memory B-
cells CD27
+
IgD
-
IgM
-
 (SMB)
1,5–7,16
. SMB develop in the germinal centers of lymph-
nodes, in a T-dependent-manner, and therefore their reduction may result from 
functional defects in either B or T helper cells and correlates with levels of 
immunoglobulin secretion
17
. A severe reduction in SMB cell type was associated with a 
greater risk of granulomatous disease and splenomegaly
16
. Transitional B-cells CD38
++
 
IgM
++
 (TR) are early bone marrow (BM) emigrants which do not proliferate, but 
instead differentiate into naïve mature B-cells in healthy controls. However, in some 
CVID patients TR B-cells frequency is increased and, being the most immature form of 
B-cells detectable in peripheral blood, this probably represents a block in the early 
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differentiation of mature B-cells
7,18
. TR B-cells expansion was associated with higher 
risk of lymphadenopathy
16
. Additionally, the expansion of the CD21
low
CD38
low
 B-cells 
(CD21lo) subset, which is very infrequent in healthy individuals, characterized by low 
CD21 expression, has been associated with splenomegaly and autoimmune 
cytopenia
16,18,19
.  
Besides imbalances in B-cell subsets, CVID is frequently associated with T-cell 
abnormalities such as persistent T-cell activation, loss of naïve CD4 T-cells and 
impairment of regulatory T-cells (Treg), which are reported even in patients receiving 
replacement therapy with IgG
5,7,20,2122,23
. The significant reduction of naïve CD4 T-cells 
in CVID patients could be explained by both reduced thymic output and increased 
spontaneous apoptosis and cell turnover
22
. In contrast to CD4
 
T-cells, the CD8
 
T-cells 
may expand, explaining the inverted CD4/CD8 T-cell ratio often seen in CVID
1
. 
It is not clear which of the T and B-cells abnormalities are possibly causative, and 
which are secondary or only epiphenomena
24
. 
Several attempts have been done to establish correlations between immune and clinical 
phenotypes in CVID. In 2002 the Freiburg classification divided patients into three 
groups through the analysis of the frequency of different B-cell populations, based on 
the expression of IgM, IgD, CD27 and CD21
1,25
. Other classification scheme was the 
Paris classification, which distinguished patients based on the reduction of total versus 
switched memory B-cells. Thereby, in order to unify different classification schemes 
and improve their clinical and immune phenotype correlations, the EUROclass 
classification was developed in 2008. Additionally, immunological classifications based 
on the underlying pathophysiologic B-cell background were suggested in the past to 
stratify CVID patients
18
. Notably, none of the models was able to predict autoimmune 
phenomena
16
 and the overall clinical prognosis still imposes a major challenge
18
. 
Despite recent progress in the discovery of different gene defects associated with CVID, 
these are considered to cause only 10-20% of the cases in large cohorts
26
, and frequently 
in circumstances of consanguinity, suggesting that this syndrome results from polygenic 
rather than monogenic causes
5,7
. The key genetic mutations in CVID affect the 
inducible co-stimulator gene (ICOS)
1,2,27–30
, genes that encode for B-cell antigen 
receptor associated complex (CD19, CD21 and CD81)
1,2,30–34
, B-cell activating factor 
receptor (BAFF-R)
2,33,35
, CD20
36
, and the BCR transmembrane activator and calcium-
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modulating cyclophilin ligand interactor (TACI)
1,2,29,30,33,35
. However, mutations in 
TACI should be considered as disease modifying rather than disease-causing, because 
they are not specific of immunedeficient patients
1,2,6,7
. 
Nowadays the gold-standard treatment for CVID patients is immunoglobulin 
replacement therapy (IgG), which is known to reduce the frequency of infections and 
the progression of some complications
2,37
. IgG is administered regularly to patients 
either by intravenous or subcutaneous infusion. The usual dosage for intravenous 
immunoglobulin (IVIg) replacement is 100–150 mg/kg/week and 100 mg/kg/week for 
subcutaneous immunoglobulin, nevertheless individual dosage is usually defined 
according to maintenance of a target serum immunoglobulin (IgG trough level of at 
least 500-700mg/dl) and/or to prevent invasive or aggressive infection
1,2,38,39
. Recently, 
it has been hypothesized that the benefits of IgG therapy are not only related to antibody 
replacement but also to its ability to modulate the immune response
37
. In addition, 
management of these patients includes adequate infection control with antibiotic and 
treatment of eventual complications.  
The immunologic and clinical heterogeneity of CVID hampers the discovery of 
underlying disease-causing mechanisms, genetic defects and clinical relevant prognostic 
factors. 
This study aims to characterize the clinical and laboratory phenotype of CVID patients 
through the analysis of the largest Portuguese cohort followed in one single Centre in 
2015. Additionally, we aim to address the correlations between immune-phenotype and 
clinical manifestations and to evaluate their stability in CVID patients. For this last 
objective we focus our analysis in a subgroup of 29 patients, from whom we have 
detailed clinical and immunological evaluations performed in 2008
35,40,41
.   
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Materials and Methods 
 
Study Design 
A total of 60 adult (36 females) CVID patients, 58 of which currently under follow-up 
in Centro de Imunodeficiências Primárias (CIDP), from Hospital de Santa Maria, were 
included in this study. Two females were deceased at the time of the study (2015).  The 
patients were diagnosed according to European Society for Immunodeficiency (ESID) 
criteria
101
 and/or to Primary Immunodeficiency Expert Committee (PID EC) of the 
International Union of Immunological Societies (IUIS), which stated that the criteria for 
the diagnosis of CVID are based on the severe reduction in at least 2 serum 
immunoglobulin isotypes (low IgG and IgA and/or IgM), with normal or low number of 
B cells, and presence of variable clinical phenotypes: most have recurrent infections, 
some have polyclonal lymphoproliferation, autoimmune cytopenias and/or 
granulomatous disease
42
.  
Clinical and immunological data from 60 CVID patients were collected and filled in an 
online database specifically designed for PID/CVID patients. All the data were then 
analyzed and the correlations between immune phenotype and clinical manifestations 
were performed.  
All subjects gave written informed consent for blood sampling and processing. The 
study was approved by the Ethical Board of the Faculty of Medicine of the University 
of Lisbon and of the Hospital de Santa Maria, and performed in accordance with 1964 
Declaration of Helsinki and its later amendments. 
 
Data collection 
Clinical and epidemiological data from the 60 patients were assessed retrospectively 
through the rigorous consultation of the medical records. The information collected 
regarding each patient included the date of birth, date of the first study, date of the last 
medical record, duration of follow-up, age/type of first symptom suggesting PID, age at 
the diagnosis, the age at the beginning of treatment, the frequency of treatment with 
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antibiotics in the previous year, the current weight, the type/dose of replacement 
treatment with immunoglobulin G (subcutaneous or endovenous) and other therapeutics 
required. Furthermore, the delay of diagnosis was calculated based on the difference of 
the age at first symptoms and the age at diagnosis. The duration of follow-up resulted 
from the difference between the first medical record and the date of the last medical 
record. The dose of IgG was calculated in mg/kg/month.  
Regarding the current clinical phenotype, it was described if each patient presented 
autoimmune disease (AID), autoimmune cytopenias, splenomegaly, adenopathies, 
evidence of lymphoid proliferation, chronic diarrhea, malignancies, bronchiectasis and 
infections only.  
The criteria for diagnosis were as follows:  
Autoimmune disease - included psoriasis, thyroiditis, vitiligo, Crohn’s disease, celiac 
disease, seronegative arthritis, rheumatoid arthritis, Sjögren's syndrome, SLE, type 1 
diabetes mellitus and alopecia total. Concerning autoimmune cytopenias it was 
identified ITP, AIHA, autoimmune neutropenia, autoimmune leucopenia, pernicious 
anemia and Evans syndrome. Noteworthy, the diagnostic criteria for autoimmune 
disease, were mainly clinical data, given the impairment in antibody production.     
Lymphoid proliferation - it was documented if at least one of the following histologic 
patterns were present: gastrointestinal lymphoid infiltrate, lymphoid interstitial 
pneumonitis (LIP) or granulomatous disease on gastrointestinal, lymph node or 
pulmonary biopsies. Biopsies were performed in 51 patients. 
Splenomegaly - longitudinal spleen diameter superior to 13 cm by computer 
tomography or ultrasonography. 
Adenopathies - report of lymph node larger than 1 cm diameter in 2 or more lymphatic 
chains in clinical and/or imaging exams. 
Chronic diarrhea – clinically or laboratory findings of chronic or recurrent diarrhea. 
It is important to take in consideration that each individual might have more than one 
complication. 
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The immunological characterization was based on results of B and T-cell subsets 
immunephenotype using 8-colour flow-cytometry, available in the files of 52 patients.  
These data were compared with 15 age-matched healthy individuals. The laboratory 
data results quantified the number of total lymphocytes and the absolute number and the 
percentage of CD19, CD3, CD4, CD8 and NK populations. Regarding the subset of B 
lymphocytes, it was determined the percentage of naïve cells (CD27
-
), marginal zone 
cells (CD27
+
IgD
+
IgM
+
), switched memory B cells (CD27
+
 IgD
-
), transitional B cells 
(CD38
hi
IgM
hi
), switched plasmablasts (CD38
hi
IgM
-
), and CD21
low
CD38
low
 subset. 
Concerning T CD4 lymphocytes, it was determined the percentage of naïve 
(CD45RA
+
CD27
+
) and activated (HLADR
+
; CD38
+
HLADR
+
; CD69
+
) cells. In 
addition, regarding the T CD8 population, the percentage of naïve (CD45RA
+
CD27
+
) 
and terminally differentiated cells (CD45RA
+
CD27
-
) were also included in the study. 
Based on B-cell analysis each patient was classified according to the EUROclass 
categorization. 
 
Data analysis 
The statistical analysis was performed using GraphPad Prism 5®, version 5.03 for 
Microsoft Windows®. Given the non-normal distribution of the data, the non-
parametric Mann–Whitney test was performed for group comparisons. Results are 
expressed as mean ± standard error of the mean and median, and were considered 
significant at a p-value <0.05. 
We compared the immunological parameters in CVID groups split according to the 
presence of a given clinical manifestation and with a healthy cohort (n=15). We further 
focused our analysis in a subgroup of 29 patients from whom we have detailed clinical 
data collected during a previous study (2008)
13,35,40
. 
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Results 
 
The analysis of medical records allowed us to characterize the CVID cohort under 
follow-up regarding different epidemiological and clinical variables (Suplementary 
Table 1). 
 
Demographic data 
The age of the patients ranged from 21 to 78 years, with a mean of 44.6 ± 12.7years old. 
The age at onset of symptoms ranged from 1 to 60 years and was most commonly 
during the second decade (mean 18.4 ± 15.4years; median 18) and mean age at 
diagnosis was 32.3 ± 14years (median 32.5), with no significant differences between 
gender, regarding the onset of symptoms and age at diagnosis (p=0.981 and p=0.457, 
respectively).  
The mean diagnostic delay was 13.9 ± 12.3years (median 10.5). 
 
Length of follow-up and overall mortality 
This cohort had a median follow-up time of 8.5 years. Of the total 60 individuals, two 
females were deceased at the time of the present study, both of them died from solid 
malignancies, specifically triple negative breast carcinoma and gastric adenocarcinoma 
at the age of 43 and 40 years old, respectively. 
 
Initial symptoms and diagnosis 
In most patients the initial symptoms were recurrent respiratory infections (63%) and 
in 18% were lower respiratory tract infections. In 32% of the patients, the initial 
symptom was chronic diarrhea. AID was present as first manifestation in 12% of the 
total cohort, corresponding to autoimmune cytopenia in 86% of these, specifically ITP. 
Three patients presented severe infections, namely meningitis and poliomyelitis as first 
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manifestations (at the ages of 3 and 6 months, respectively), two patients had urinary 
tract infections and one had recurrent abscesses. 
We compared the mean age at diagnosis of the patients that present of each clinical 
manifestation, with the mean age at diagnosis of the individuals who do not and, with 
mean age at diagnosis of total CVID. Remarkably, there was no significant difference in 
the mean age at diagnosis of patients first presenting with respiratory infections as 
compared to the rest of the patients. Among different clinical manifestations, our data 
shows that the age of diagnosis of patients presenting with splenomegaly (mean 28.9 ± 
13.2years, median 29) was significantly lower compared with patients with chronic 
diarrhea (mean 35 ± 14.3years, median 37), (p= 0.048).  There were no other significant 
differences in the age of diagnosis regarding the different clinical phenotypes. 
The diagnosis delay ranged from 0 to 44 years, with a mean of 13.9 ± 12.3years 
(median 10.5). There were no significant differences in the diagnosis delay regarding 
the different clinical phenotypes. 
 
Clinical manifestations of CVID 
The review of the medical records 
revealed that, as shown in Table 1, at 
the time of the last medical 
observation, 34 out of 60 patients 
(57%) presented AID. Specifically, 19 
patients presented autoimmune 
cytopenias (32%), including ITP (14), 
AIHA (5), autoimmune neutropenia 
(4), Evans syndrome (1), autoimmune 
leucopenia (1) and pernicious anemia 
(1). Other autoimmune diseases were 
found in 21 patients (35%), including 
psoriasis (5), thyroiditis (7), vitiligo 
(3), Crohn’s disease (3), celiac disease 
(2), seronegative arthritis (2), 
Table 1- Clinical characterization of the cohort. 
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rheumatoid arthritis-like (2), Sjögren's syndrome (2), SLE (1), type 1 diabetes mellitus 
(1) and alopecia total (1). 
Splenomegaly was reported in 34 patients (57%) and adenopathies in 31 (52%). 
Interestingly, 22 patients (37%) showed both simultaneously. Patients 8 and 12 were 
splenectomized at the age of 51 and 22 years old, respectively, in context of ITP. 
Histological evidence of lymphoid proliferation was found in 43 patients, being 72% 
of the total cohort and 84% among the 51 patients that were submitted to biopsies 
during follow-up. Interestingly, 1 of the 4 patients that had not been submitted to 
biopsies in 2008 (patient 56) has gastrointestinal biopsies that present lymphoid 
proliferation. Moreover, granulomatous disease was documented in ten individuals 
(17%) and LIP in five (8%). Forty-one patients were documented with gastrointestinal 
lymphoid infiltrate, mainly nodular lymphoid hyperplasia (20 patients, 33%). 
Clinical or laboratory findings of chronic or recurrent diarrhea were reported in 
forty-two patients (72%) and bronchiectasis in 35, by chest CT (58%). 
Malignancy occurred in 8 patients (13%), including 4 neoplasms from the 
gastrointestinal tract (3 gastric carcinomas - patients 31, 54 and 59, and 1 rectal 
carcinoma -patient 41), 3 skin carcinomas (1 squamous-cell carcinoma - patient 15 and 
2 basal-cell carcinoma - patients 44 and 58) and 1 breast cancer (patient 6).  
Noteworthy, only 3 patients (5%) did not present any complication besides infections 
(not considering bronchiectasis as a clinical phenotype). 
 
Immunoglobulin replacement therapy  
Fifty-six patients were currently on regular immunoglobulin replacement therapy with 
highly variable doses and periodicity, adapted to each patient’s weight and clinical 
condition. The majority (70%) of the cohort was under endovenous IgG, with a mean 
dose of 629.6 ± 214.5mg/kg/month (median 635). The remaining 30% was under 
subcutaneous IgG, with a mean dose of 595.4 ± 380mg/kg/month (median 419). 
At the time of the study 2 of the 58 patients alive have not started IgG replacement 
therapy. The age at the beginning of the IgG replacement therapy ranged from 5 to 67 
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years old with a mean age of 34.4 ± 13.9years (median 36, n=58). The treatment had a 
mean duration of 10.6 ±6.7 years (median 10) and ranged from 1 to 27years (n=56). 
 
Other therapeutics 
Twenty-four individuals were under immunossupressive therapy. Seventeen were under 
corticotherapy, although only one was being treated with a dose above 20mg/day. 
Immunossupressive drugs, namely methotrexate, cyclophosphamide and cyclosporine, 
were being used in four patients for malignancy, granulomatous disease and 
seronegative rheumatoid arthritis. Infliximab was being used in one patient in the 
management of seronegative arthritis. Salazopyrin and mesalazine, were in use in nine 
patients, mainly because of enteropathy, and hydroxychloroquine in one patient with 
SLE and in another one with RA-like arthritis. 
 
Overlap of the clinical manifestations 
Our results show that the majority of the clinical manifestations and/or signs and 
symptoms do overlap. Regarding the following: autoimmune disease, 
lymphadenopathies, lymphoid proliferation, splenomegaly, chronic diarrhea and 
bronchiectasis, we calculated the frequency of different clinical manifestations per 
patient. We found that each patient presented an average of four of the previous 
manifestations (mean 3.6 ±1.7; median 4) and that 75% of the patients presented three 
or more different clinical phenotypes and/or signs and symptoms. In fact, the larger 
group of CVID patients, present in Figure 1, manifests simultaneously autoimmune 
disease and lymphoid proliferation (n=21). Regarding signs and symptoms, in Venn 
diagram in Figure 2, the larger group of patients manifests at the same time 
adenopathies, diarrhea, bronchiectasis and splenomegaly.  
 From immune phenotype to clinical manifestations in CVID                         Page 17 of 37 
Clinical Phenotypes
0 5 10 15 20 25
Autoimmune
 disease
Lymphoid
proliferation
Infections-only
Malignancy
2008
2015
Number of patients
 
Stability of the clinical manifestations 
In order to evaluate the stability of the clinical phenotype in CVID patients we focused 
our analysis in a subgroup of 29 patients from whom we have detailed clinical and 
immunological evaluations performed in 2008
35,40,41
. We compared the current clinical 
manifestations with the previously recorded phenotypes and the results are shown in 
Figure 3 and Figure 4.  
 
 
We were able to show that the spectrum of clinical manifestations expanded despite 
replacement IgG treatment. We observed that regarding autoimmune diseases, five 
patients presented cytopenias during the follow-up of seven years, specifically primary 
immune thrombocytopenia. Splenomegaly improved in two cases and was recorded for 
the first time in four patients, while adenopathies cleared in one patient and were first 
Signs and Symptoms
0 5 10 15 20
Splenomegaly
Adenopathies
Chronic Diarrhea
Bronchiectasis
2008
2015
Number of patients
Figure 3- Comparison of the evaluations of signs and 
symptoms performed in a group of 29 patients in 2008 
and 2015. 
Figure 4- Comparison of the evaluations of clinical 
phenotypes performed in a group of 29 patients in 
2008 and 2015. 
Figure 1 - Venn diagram with the representation of the 
overlap of the clinical manifestations. DAI - Autoimmune 
disease. 
Figure 2 - Venn diagram with the representation of 
the overlap of the signs and symptoms. 
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reported in five. Ten patients revealed de novo gastrointestinal lymphoid infiltrates, 
LIP was documented in one more patient and granulomatous disease in five more 
patients. Overall, ten more patients present histological evidence of 
lymphoproliferation in 2015. During the follow-up, a neoplasm was diagnosed in six 
patients and bronchiectasis in two patients. Finally, eleven patients started to have 
clinical manifestations of chronic diarrhea and three patients reported improvement of 
these complains.  
 
Immunological characterization 
In 52 patients we analyzed B-Cells and T-cells immune-phenotype, namely in order to 
evaluate the frequency of the most frequently reported disturbances in CVID in our 
cohort (Supplementary Table 2).  
In contrast with an age-matched healthy cohort, our CVID patients showed decreased 
frequency of naïve CD4 T-cells (mean 26.4 ± 21.9%, median 20.4), as compared to 
mean 42 ± 12.3%, median 43.1, (p= 0.0029, Figure 6) and increased immune activation 
of CD4 T-cells, as evaluated by the frequency of expression of HLA-DR within CD4 T-
cells (mean 13.9 ± 10%, median 11.4), as compared to mean 5.4 ± 2%, median 5.5 
regarding the healthy cohort, (p= 0.0006, Figure 7).  
The CVID cohort presented an expansion of abnormal CD21
low
CD38
low
 B-cells (mean 
18.8 ± 18%, median 11.5), as compared to the healthy cohort (mean 4.1 ± 2.4%, median 
3.4), (p=0.0003, Figure 8). 
CVID patients have been classified according to the frequency of the above mentioned 
B-cell sub-populations. The stratification of our CVID cohort according to the 
EUROclass classification is represented in Figure 5
16
. This classification divides the 
patients in groups with circulating B-cells comprising less than 1% of lymphocytes “B-“ 
and more than 1% “B+”. Within the “B+” subset, patients with less than or equal to 2% 
of switched memory B-cells are grouped into “SmB-“ or “SmB+”, respectively. 
Additionally, expansion of transitional B
-
cells (more than 9%) and CD21lo B-cells 
(more than 10%) also determine different categories
1,25,43
. 
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Our results revealed no major differences in the distribution of the patients among 
different Euroclass categories, compared with the results previously reported in the 
European multicenter trial (n=303)
43
, except for the increased relative proportion of 
SmB
+
21
low
 patients (p=0.0008). 
 
 
 
 
 
 
 
 
 
Comparison between clinical and immunologic features  
We compared the immunological phenotype among CVID groups split according to the 
presence of a given clinical manifestation (Supplementary Table 3 and Supplementary 
Table 4) and with a healthy cohort (n=15). 
Our results revealed, as shown in Supplementary Table 3, that patients with 
splenomegaly presented statically lower total number of lymphocytes (mean 1397 ± 
1012cells/μL, median 1040) and CD4 T-cell count (mean 585.8 ± 441cells/μL, median 
445) compared with CVID patients without this manifestation (mean 1816 ± 
612.3cells/μL, median 1840; p=0.01 and mean 736.8 ± 316cells/μL, median 69; 
p=0.0351; respectively). Bronchiectasis were present in patients with statically lower 
number of CD19
+ 
cells (mean 6.2 ± 5cells/μL, median 3.8), as compared with patients 
without this complication (mean 35.45 ± 106.4 cells/μL, median 8.2; p= 0.0279). The 
group of patients presenting chronic diarrhea was not correlated with any immunologic 
feature.  
Figure 5- Patients distribution according to EUROclass B-cell subpopulations. The number of patients 
included in each category and respective frequency in the total cohort  are indicated. 
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Patients with autoimmune cytopenias, splenomegaly and adenopathies present 
significantly higher levels of naïve CD4 T-cell loss (Figure 6). Additionally, 
significantly higher levels of expression of T-cell activation markers were observed in 
association with autoimmune cytopenias, splenomegaly, adenopathies and lymphoid 
proliferation (Figure 7).   
 
 
Moreover, autoimmune cytopenias,   
splenomegaly, adenopathies and lymphoid 
proliferation were associated with 
significant expansion of CD21
low
CD38
low
 
(Figure 8).  
Clinical correlations of our cohort 
according to EUROclass categories 
revealed that the group of patients within 
SmB
-
21
low
 group presented higher 
frequency of autoimmune diseases 
(p=0.0157),  compared with the patients 
SmB
-
21
norm
, as well as the individuals B
+
SmB
-
Tr
norm
 in comparison with those B
+
SmB
-
Tr
hi 
(p=0.0013). Additionally, we also found that patients within SmB
+
21
low
 group 
compared with SmB
+
21
norm
 patients, presented higher frequency of splenomegaly 
Figure 6 –Loss of naïve T-cells in patients with CVID; 
comparison between total cohort, healthy individuals, 
and patients with different clinical phenotypes. 
Figure 7- Immune activation in patients with CVID; 
comparison between total cohort, healthy individuals, and 
patients with different clinical phenotypes.  
Figure 8- Expansion of of abnormal CD21lowCD38low B-cells 
in patients with CVID; comparison between total cohort, 
healthy individuals, and patients with different clinical 
phenotypes. 
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(p=0.003), whereas those SmB
-
21
low 
presented higher frequency of adenopathies, when 
compared with the SmB
-
21
norm 
individuals. 
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Discussion 
 
We reviewed epidemiologic, clinical and immunological characterization from a cohort 
of sixty adult CVID patients (36 females and 24 males) that have been followed in 
Hospital de Santa Maria (Centro Hospitalar Lisboa Norte), during a mean follow-up 
time of 8.5 years.  The database specially designed for PID/CVID patients and filled 
with all of the clinical information, regarding the sixty patients, will be used for the 
medical record of PID patients in the future. 
In our study the onset of symptoms was most common during the end of the second 
decade (mean 18.4 ± 15.4years; median 18) which is slightly earlier when compared 
with the results of other cohorts
3,16,44,45
. In contrast, a more recent European study 
reported a mean age of onset of 1 to 5 years, which was probably biased by the 
predominant inclusion of pediatric centers
46
. 
Regarding the initial symptoms, our study reported similar results to the Quinti et al. 
observations’ that respiratory tract infections were the most prominent clinical problem 
at diagnosis, occurring in 65% of the patients
11
. Autoimmune diseases were the first 
symptoms present in 12% of the cohort, which is also very similar to previous studies
11
. 
Due to the struggle related to the definition of the first symptoms of CVID, such as the 
cut off between the normal recurrent respiratory infections expected during the infancy 
and the recurrent respiratory infections caused by CVID, we compared the difference 
between the age at first symptoms when we take into account or not these 
manifestations. We calculated the mean age at first symptoms of the total cohort: 1) 
considering recurrent respiratory infections of the infancy and ascribing the age of 2 
years, and 2) considering the following manifestations as the initial presentation of 
CVID. The results were not significant different (p=0.23) between the consideration, or 
not, of the respiratory infections during childhood as the first manifestations of CVID to 
the age of onset (mean 16.2 ±14.9 and mean 19.1±15.1years, respectively). 
The average age at diagnosis was 32.3 years, which is similar to the reported in the 
literature
3,11,16,44,45
. The mean diagnostic delay was 13.9 years, which is slightly later 
when compared with previous studies 
11,16,45,47
, and possibly explained regarding the 
earlier mean onset of symptoms. Among different clinical manifestations, our data 
shows that the age of diagnosis of patients presenting with splenomegaly was 
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significantly lower compared with chronic diarrhea. This finding could probably be 
explained by the fact that medical doctors correlate more some specific clinical 
manifestations to immunodeficiency, and tend to be more aware of the diagnosis in 
those cases.  
During follow-up, 55% of the patients presented autoimmune phenomena which is 
very high compared to the 25-48% documented
3,11,45
, nevertheless, as in previous 
studies, ITP and AIHA were the most common immune cytopenias
3,16
. Chronic diarrhea 
was observed in 72% of the patients, which is also higher than reported. This difference 
might be due to the fact that we considered both infectious and non-infectious causes 
for chronic diarrhea. Furthermore, also splenomegaly, bronchiectasis and 
gastrointestinal lymphoid infiltrate, mainly nodular lymphoid hyperplasia, were more 
frequently reported in our cohort compared to what was previously reported in the 
literature, which could reflect the fact that a lot of manifestations were underdiagnosed 
until the availability of better diagnostic procedures in patients periodically followed up. 
Interestingly, two Portuguese studies from 2012 and 2011, that followed a cohort of 
twenty-four CVID patients in Centro Hospitalar do Porto
48
 and fourteen CVID patients 
in Centro Hospitalar e Universitário de Coimbra
47
, respectively, during an identical time 
of follow-up, had similar results regarding the higher proportion of patients presenting 
some of the clinical features mentioned, in comparison with studies from other 
countries. One possible explanation for these results could be related to the similar 
genetic pool of the Portuguese population or to the fact that patients are only referred to 
a specialized Centre later in the course of the disease. On the other hand, only 5 %, of 
the patients did not present any complication besides infections, which is much lower 
compared with similar studies (26-32%)
3,45,47
. 
Chapel H. et al.has focused the importance of clinical phenotyping, and its value for 
prognosis, through the definition of 5 distinct clinical phenotypes: no complications, 
autoimmunity, polyclonal lymphocytic infiltration, enteropathy, and lymphoid 
malignancy
45
. Moreover, even though, regarding this categorization, 83% from a total 
of 334 CVID patients had only one of these phenotypes
45
, our results showed that by 
considering clinical manifestations as malignancy, lymphoid proliferation, 
autoimmunity, infections-only, the majority of the clinical manifestations do overlap, 
which supports the struggle in establishing homogeneous and stable groups of clinical 
phenotypes
45,49
.  
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Regarding the correlations between clinical and immunological phenotypes, we 
found that autoimmune cytopenias, splenomegaly, adenopathies and lymphoid 
proliferation were associated with significantly higher levels of naïve CD4 T-cell loss, 
T-cell activation markers (%HLADR
+
) and expansion of CD21
low
CD38
low
 B-cells. In 
our cohort, we found associations previously reported in EUROclass trial, namely 
association of expanded CD21
low
 B-cells with splenomegaly and granulomatous disease 
(lymphoid proliferation)
16
 and is also in accordance with the relation with splenomegaly 
and autoimmune disease, reported by Moratto et al.
17
. In addition, our data also 
resemble the Mouillot et al. and Bateman et al. results regarding the reduction in naïve 
CD4 T-cells and increase in activated T-cells in autoimmune cytopenias and lymphoid 
proliferation
21,22
. Finally, as Lanio et al. we also report that lower levels of naïve CD4 
T-cells are more frequently observed among patients with splenomegaly
23
.  
The longitudinal analysis of a subgroup of twenty-nine patients demonstrated that none 
of the clinical manifestations or signs and symptoms were constant findings. In contrast 
to other studies, we observed an increase in the prevalence of autoimmune cytopenias 
during follow-up
11
. We show that the spectrum of CVID clinical manifestations in each 
individual is not stable over the time, expanding despite replacement IgG treatment, and 
as a result, that CVID is a progressive disease.  
We report the usage of slightly higher dose of IgG in the replacement therapy in our 
study, with a median dose of endovenous and subcutaneous IgG of 635 and 
419mg/kg/month respectively, compared to the usual dose of 200-600mg/kg/month
38,39
. 
This difference could eventually be justified by the higher prevalence of autoimmune 
conditions
44,46
. Moreover, it corroborates the conclusion of a large European cohort of 
2212 patients, that there is a considerable difference in the management of CVID among 
centers and that IgG dosage should be individually based on each patient’s clinical 
course
39,46
. 
Malignancy is one of the most relevant prognosis factors in CVID
3,11,44
. During the 
time of follow-up of this study, this cohort was not associated with any case of 
lymphoma, even though this is the most prevalent malignancy in CVID described in the 
literature
3,11,15,44
. Nevertheless, we documented seven cases of carcinoma during follow-
up and, as expected regarding solid tumors, two of them were gastric carcinoma
3,11,44
. 
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Mortality was low in our cohort (3%), comparable with recent studies with similar 
follow-up periods (6%)
11
. This reflects the improvement in the management of disease, 
with more accurate diagnosis and advanced treatment of the disease complications, as 
well as the more effective IgG replacement treatment protocols. 
Our study concludes that although CVID has got as hallmark a severe antibody 
deficiency, it represents a heterogeneous group of patients with a broad spectrum of 
clinical and immunological disturbances. Additional therapies are required to limit the 
progression of non-infectious complications that are main determinants of morbidity in 
CVID patients. Finally, our data also supports that targeting of T-cell imbalances may 
be a promising therapeutic strategy to be explored in the management of these patients 
in the future.  
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SUPPLEMENTARY DATA 
 
 
  
Table 1. Patients’ clinical profile 
Case 
nr 
Gender 
|Age (y) 
Age at 1st symptoms (y) 
|type 
Age at diagnosis (y) 
|Beginning IgG (y) 
AID 
Autoimmune 
Cytopenias 
Splenomegaly Adenopathies 
Lymphoid 
Proliferation 
Cancer 
Chronic 
Diarrhea 
Bronchiectasis 
IGIV/ IGSC 
|Dose (mg/kg/month) 
1 F | 33 2 | RI 27 | 30 ITP ITP Yes Yes No No No Yes iv | 729 
2 F | 33 1  | RI 10 | 10 No No No Yes Yes No No Yes sc | 1442 
3 F | 50 35 | RI 39 | 39 Pernicious anemia 
Pernicious 
anemia 
No Yes Yes No Yes No sc | 236 
4 F | 38 20 | RI 36 | 37 No No No No No No No Yes iv | 429 
5 F | 47 31 | RI 37 | 37 No No No No Yes No Yes Yes iv | 583 
6 F | 43† 26 | RI 31 | 31 No No Yes No No Yes No No iv | 256 
7 F | 35 
31|RI; UI; recurrent 
candidiasis 
33 | 33 No No No No Yes No No Yes sc | 400 
8 F | 60 39 | ITP 52 | 54 Evans Syndrome 
Evans 
Syndrome 
No No Yes No No No iv | 577 
9 F | 47 20 | RI 38 | 38 
Psoriasis; 
seronegative 
arthritis 
No Yes Yes Yes No Yes No iv | 370 
10 M | 48 25 | RI 31 | 39 No No Yes Yes No No Yes Yes sc | 560 
11 M | 48 12 | CD 37 | 45 No No Yes Yes Yes No Yes No iv | 571 
12 F | 32 18 | ITP 29 | 30 
Sjögren's 
syndrome, SLE, 
ITP, 
autoimmune 
neutropenia 
ITP, 
autoimmune 
neutropenia 
No Yes No No No Yes iv | 507 
13 F | 37 1 | Meningitis 22 | 22 Celiac disease No Yes Yes Yes No Yes Yes sc | 640 
14 F | 26 8 | RI 9 | 9 No ITP Yes Yes Yes No No Yes sc | 875 
15 M | 78 53 | RI 66 | 67 No No Yes No Yes Yes Yes Yes iv | 461 
16 F | 40 27 | ITP 27 | 27 ITP ITP Yes No No No No No sc | 515 
17 F | 45 10 | RI 40 | 40 No No No Yes Yes No Yes Yes iv | 714 
18 M | 44 39 | CD 39 | NA 
Psoriasis; Celiac 
disease 
No No Yes No No Yes No NA 
19 F | 71 55 | CD 65 | 66 No No No Yes Yes No Yes No iv | 1026 
20 F | 36 19 | Febrile syndrome 21 | 27 ITP ITP Yes Yes Yes No Yes No iv | 635 
21 M | 30 22 | CD; RI 22 |NA No No No No No No No No NA 
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22 F | 41 2 | CD 37 | 39 No No No No Yes No Yes Yes sc | 486 
23 F | 40 2 | RI 35 | 35 No No No No No No No No iv | 167 
24 M | 39 10 |RI 21 | 21 Thyroiditis No No No No No No No sc | 400 
25 M | 48 2 |RI 41 | 42 Psoriasis No Yes Yes Yes No Yes Yes sc | 660 
26 M | 28 6 | ITP 9 | 21 ITP 
ITP; 
neutropenia 
Yes Yes Yes No No Yes sc | 310 
27 M | 72 20 | RI 51 | 51 
Vitiligo; 
Thyroiditis 
No Yes Yes Yes No Yes Yes sc | 390 
28 F | 37 15 | RI 17 | 17 AIHA; ITP AIHA; ITP Yes Yes Yes No Yes Yes sc | 1600 
29 M | 50 38 | RI 39 | 39 No No Yes Yes Yes No Yes Yes iv | 702 
30 M | 48 21 | recurrent abscesses 33 | 35 No No Yes Yes Yes No No No iv  | 794 
31 M | 46 17 | RI 19 | 19 
Psoriasis; Crohn's 
disease 
No Yes Yes Yes Yes Yes Yes iv | 833 
32 F | 36 2 | RI 20 | 20 RA; AIHA AIHA Yes No No No Yes Yes iv | 1085 
33 M | 57 1 | poliomielitis 22 | 47 AIHA AIHA Yes Yes Yes No Yes Yes iv | 667 
34 F | 52 
2 |CD; recurrent 
conjutivitis 
33 | 39 
Vitiligo; 
Thyroiditis; 
Sjögren's 
syndrome; ITP 
ITP No Yes Yes No Yes No iv | 408 
35 F | 25 2 | RI 21 | 21 
Thyroiditis; DM 
type 1 
No Yes No No No Yes Yes iv | 741 
36 F | 59 2 | RI 46 | 46 No No No No No No Yes No iv | 678 
37 F | 52 22 | RI 48 | 42 ITP; neutropenia 
ITP; 
neutropenia 
Yes Yes Yes No Yes Yes iv | 697 
38 F | 47 31 | RI 37 | 37 No No No No Yes No Yes Yes iv | 536 
39 F | 55 2 | RI; CD 20 | 44 
Seronegative 
arthritis; ITP 
ITP Yes No Yes No Yes Yes iv | 727 
40 F | 65 60 |RI 62 | 63 No No No No Yes No Yes No iv | 545 
41 M | 42 2 | CD 31 | 31 
Inflamatory bowel 
disease 
ITP; 
neutropenia; 
leukopenia 
Yes No Yes Yes Yes No iv | 735 
42 F | 38 18 |RI 27 | 27 
AIHA; ITP; 
immune 
neutropenia 
AIHA; ITP; 
immune 
neutropenia; 
leukopenia 
No Yes Yes No Yes Yes iv | 1019 
43 F | 77 43 |RI 49 | 54 ITP ITP Yes No Yes No Yes Yes iv | 896 
 From immune phenotype to clinical manifestations in CVID                         Page 33 of 37 
44 F | 73 32 | ITP 63 | 64 
AIHA; ITP; 
Thyroiditis 
AIHA; ITP No No Yes Yes Yes Yes iv | 538 
45 M | 22 3 | RI 12 | 14 No No Yes Yes No No No No iv | 441 
46 M | 32 27 | RI 30 | 30 No No Yes No No No No No iv | 396 
47 M | 38 2 |CD 32 | 33 Vitiligo No Yes No Yes No Yes No iv | 635 
48 M | 48 10 | RI; CD 39 | 40 Crohn's disease No No Yes Yes No Yes Yes sc | 416 
49 M | 44 
1 | Meningitis; 
tuberculosis 
39 | 39 RA-like No Yes Yes Yes No Yes Yes iv | 936 
50 M | 51 40 | RI 42 | 42 No No No No Yes No Yes No sc | 419 
51 M | 21 1 | Otitis media 5 | 5 ITP; neutropenia 
ITP; 
neutropenia 
Yes Yes Yes No Yes Yes iv | 500 
52 M | 43 7 | RI; ITP; AIHA 16 | 38 No No Yes Yes Yes No Yes Yes iv | 606 
53 M | 39 38 | Celiac disease 38 | 38 No No Yes Yes Yes No Yes No iv | 524 
54 F | 40† 13| RI; CD 28 | 28 No No Yes No Yes Yes Yes Yes iv | 3300 
55 F | 40 30 | RI 32 | 31 No No No No No No Yes No iv | 426 
56 F | 44 29 | RI 31 | 31 No No No No Yes No No No iv | 132 
57 F | 45 18 | RI 39 | 39 Thyroiditis No No No Yes No Yes No sc | 414 
58 F | 36 4 | RI 7 | 12 Thyroiditis No No No No Yes Yes Yes iv | 678 
59 F | 36 16 |alopecia 34 | 18 Total alopecia No Yes Yes Yes Yes Yes Yes iv | 909 
60 M | 47 21 | CD 21 | 21 Psoriasis No Yes No Yes No No Yes sc | 359 
 
     † - patient deceased at the time of the study 
     RI – respiratory infection; UI- urinary infection; ITP – primary immune thrombocytopenia; CD – chronic diarrhea; AIHA – autoimmune hemolytic anemia; RA - rheumatoid arthritis; SLE – systemic lupus erythematosus 
     NA – not applicable 
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Table 2. Patients’ immune phenotype 
                  
Case 
Nr 
Lymph 
Total 
lymph  
cells/μL 
CD19+ 
% 
NK 
% 
CD3 
% 
CD4 
cells/μL 
CD8 
% 
B-
cells 
CD27
-
% 
CD27
+
IgD
-
% 
CD38
hi
IgM
hi
 
% 
CD21
lo
CD38
lo
 
% 
EUROclass 
CD4 T-
cells 
CD45RA
+
CD27
+
 
% 
HLADR
+
 
% 
CD38
+
HLADR
+
 
% 
1 
 
1970 9,1 3,4 76,5 697 36,3 
 
87,5 0,4 1,2 11,5 B
+
 smB
-
 Tr
norm
 21
lo
 
 
16 11,2 8,7 
2 
 
2400 4,08 6,74 87,9 938,77 47,8 
 
93,42 0,75 3,45 22,18 B
+
 smB
-
 Tr
norm
 21
lo
 
 
40,1 12 7,79 
3 
 
1900 21,5 10,56 67,2 768,63 30,8 
 
82,37 2,34 4,53 3,13 B
+
SmB
+   
Tr
 norm; 
21
norm
 
 
17,3 6,24 3,49 
4 
 
1080 10,6 6,4 77,4 438 31,4 
 
80,3 2 1,8 6,04 B
+
 smB
-
 Tr
norm 
21
norm
 
 
11 10,5 7,8 
5 
 
1400 2,74 3,38 91,1 737,18 40,4 
 
95,83 1,24 7,36 7,41 B
+
 smB
-
 Tr
norm 
21
norm
 
 
95,7 6,17 3,96 
6 
 
1800 9,6 24,99 64,1 740,74 31,2 
 
72,37 1,36 1,68 19,29 B
+
 smB
-
 Tr
norm
 21
lo
 
 
39,5 6,2 4,82 
8 
 
1840 3,3 
 
88,1 949 32,3 
 
97 0,4 13,2 34,3 B
+
SmB
-
Tr 
hi 
21
lo
 
 
48,5 14,2 9,5 
9 
 
1000 14,18 7,84 75,2 495,57 24,3 
 
86,38 3,25 6,27 14,76 B
+
SmB
+
Tr
 norm; 
21
lo
 
 
20,4 6,22 3,32 
10 
 
1100 1,45 8,03 86 323,53 61 
 
88,96 4,81 9,28 1,36 B
+
SmB
+
Tr 
hi 
21
norm
 
 
54,9 8,04 4,74 
11 
 
510 8,1 
 
76 218 28,1 
 
83,9 1,6 0,2 10,7 B
+
 smB
-
 Tr
norm
 21
lo
 
 
0,9 51,7 46,4 
13 
 
770 1 5,4 91,9 330 43,3 
     
B
-
 
 
22,6 7,8 6,3 
14 
 
500 3,42 10,56 83,6 291,35 22,9 
 
84,22 3,8 0,77 10,21 B
+
SmB
+
Tr
 norm; 
21
lo
 
 
3,61 17,3 12,3 
15 
 
1400 10,42 10,42 78,7 444,03 45,6 
 
38,02 11,55 1,06 21,15 B
+
SmB
+
Tr
 norm; 
21
lo
 
 
9,44 10,5 5,08 
16 
 
2000 6,43 5,12 86,8 1009,76 37,8 
 
78,75 2,12 4,6 40,75 B
+
SmB
+
Tr
 norm; 
21
lo
 
 
8,75 25,8 17,5 
18 
 
1870 10.6 1,6 81,7 886 31 
 
77,1 5,8 2,6 7,3 B
+
 smB
+ 
21
norm
 
 
38,3 5 2,5 
19 
 
440 1,9 42,1 49,7 121 20 
 
98,6 1 0 33,9 B
+
 smB
- 
Tr
norm 
21
lo
 
 
15,7 26,9 25 
20 
 
800 5.02 9,27 77,7 518,41 12,3 
 
87,01 0,92 14,18 30,25 B
+
SmB
-
Tr 
hi 
21
lo
 
 
8,6 30,9 27,1 
21 
 
1720 13,4 
 
61,6 506 18,5 
 
92 1,4 0,8 0,7 B
+
 smB
-
 Tr
norm 
21
norm
 
 
39,4 5,5 3 
22 
 
1810 15,9 
 
68,5 643 28,8 
 
33,1 7,7 0,4 6,1 B
+
 smB
+ 
21
norm
 
  
11,2 8,9 
24 
 
1230 0,3 12,2 78,9 139 63,3 
     
B
-
 
 
77,5 2,8 1,4 
26 
 
600 7,09 7,36 79,1 212,62 48,3 
 
94,16 0,53 12,75 6,07 B
+
SmB
-
 Tr 
hi
 21
norm
 
 
10 36,5 32 
27 
 
5400 3,4 26,78 68,6 2037,42 37,3 
 
75,36 0,68 5,16 53,51 B
+
 smB
-
 Tr
norm
 21
lo
 
 
4,66 31,3 24,4 
28 
 
610 3,6 23,2 62,6 263 16,8 
 
99,9 0,1 0 56,6 B
+
 smB
-
 Tr
norm
 21
lo
 
 
8,6 18,8 16,2 
29 
 
650 0,6 4,4 51,4 122 30,5 
     
B
-
 
 
21,1 15,5 8,5 
30 
 
1749 14 1,8 82 735 36 
 
2,7 <0,1 
  
B
+
 SmB
-
 
 
41 9 5 
31 
 
1000 1,81 2,9 92,5 539,28 37 
 
86,82 3,55 4,06 48,19 B
+
SmB
+
Tr
 norm; 
21
lo
 
 
11,5 14,2 11,1 
32 
 
1700 <1 10,88 87,2 421 70,4 
     
B
-
 
 
32,1 12 9,57 
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33 
 
1240 1,5 2 87,7 317 54,1 
 
90,9 0,7 9,2 31,8 B
+
SmB
-
Tr 
hi 
21
lo
 
 
35,8 16,4 10,7 
34 
 
2500 4,35 12,31 81,1 1419,25 70 
 
96,92 0,31 13,01 18,1 B
+
SmB
-
Tr 
hi 
21
lo
 
 
9,87 20,9 11,9 
36 
 
2300 6,32 10,29 81,1 1247,89 30,6 
 
75,66 2,51 1,01 4,52 B
+
SmB
+
Tr
 norm; 
21
norm
 
 
15,1 8,53 4,16 
37 
 
930 6,2 
 
86,6 565 22,8 
 
95,3 0,8 0 13 B
+
 smB
-
 Tr
norm
 21
lo
 
 
4,1 22,1 18 
38 
 
1300 3,25 5,5 90,6 619,52 45,4 
 
94,6 0,87 1,98 4,83 B
+
 smB
-
 Tr
norm 
21
norm
 
 
92 6,97 3,7 
39 
 
2900 11,01 6,63 82,2 1377,84 38,3 
 
60,93 1,93 4,12 39,54 B
+
 smB
-
 Tr
norm
 21
lo
 
 
21,4 7,95 3,92 
40 
 
1960 12,7 5,7 74,8 904 25 
 
83 1,7 3,2 9 B
+
 smB
-
 Tr
norm 
21
norm
 
 
46,2 5,1 3,6 
41 
 
700 10,76 4,03 81,6 470,67 13,1 
 
82,51 2,05 4,09 21,62 B
+
SmB
+
Tr
 norm; 
21
lo
 
 
20,4 6,22 3,32 
42 
 
1900 6,28 4,7 88,4 694,82 31,8 
 
93,82 0,29 13,21 35,4 B
+
SmB
-
Tr 
hi 
21
lo
 
 
4,11 12,3 10,3 
43 
 
600 2,74 7,5 84 352,3 17,5 
 
95,16 1,01 32,59 2,85 B
+
SmB
-
 Tr 
hi
 21
norm
 
 
24,1 11,6 7,42 
44 
 
2100 5,92 13,27 78,9 845,02 44,7 
 
88,59 1,06 0,22 12,32 B
+
 smB
-
 Tr
norm
 21
lo
 
 
9,78 15,7 9,88 
46 
 
2790 8,2 2,4 86,7 840 48,6 
 
67 1,5 7,8 7,7 B
+
 smB
-
 Tr
norm 
21
norm
 
 
22,9 12,4 7,7 
47 
 
1040 10,4 1,2 82,6 445 33,8 
 
94,3 0,5 3,3 0,5 B
+
 smB
-
 Tr
norm 
21
norm
 
 
28,9 10,8 6,3 
48 
 
3400 15,86 15,44 67,4 621,02 63,1 
 
94,87 0,24 6,38 3,3 B
+
 smB
-
 Tr
norm 
21
norm
 
 
16,9 15,4 6,84 
49 
 
700 10,2 
 
78,4 145 53,4 
 
97,4 0,9 5 0,9 B
+
 smB
-
 Tr
norm
 21
lo
 
 
14,8 24,3 20,4 
50 
 
1600 4,91 11,57 80,2 541,51 31,2 
 
94,15 1,46 5,25 8,46 B
+
 smB
-
 Tr
norm 
21
norm
 
 
27,1 7,33 3,99 
51 
 
2480 0,8 
 
92,9 1433 29,2 
     
B
-
 
 
5,3 38,5 30,7 
52 
 
1830 17,6 
 
80,1 937 25 
 
97,7 0,1 0,1 45,3 B
+
 smB
-
 Tr
norm
 21
lo
 
 
6 13 11,7 
53 
 
1550 5,3 6,6 82,9 330 36,5 
 
76,3 2,6 2 10,3 B
+
 smB
+ 
21
lo
 
 
14,5 16,3 9 
54 
 
1800 <1 5,47 90 1163,16 25,7 
     
B
-
 
 
38,9 2,95 1,85 
55 
 
1480 7,9 
 
84,2 696 29,3 
 
96 0,3 1,4 0,4 B
+
SmB
+
Tr
 norm; 
21
norm
 
 
49 4,8 2,7 
56 
 
2400 8,27 10,45 78,1 1128,39 32,6 
 
71,15 8,2 6,53 8,29 B
+
SmB
+
Tr
 norm; 
21
norm
 
 
47,2 9,64 5,59 
58 
 
1500 11,34 6,23 80,1 629,59 41,6 
 
60,63 2,17 0,04 14,88 B
+
SmB
+
Tr
 norm; 
21
lo
 
 
36,6 5,11 2,77 
59 
 
480 2,2 4,8 86,5 284 26 
 
82,1 7,1 0,2 78,6 B
+
 smB
+ 
21
lo
 
 
2,2 13,8 11,9 
60 
 
700 3,41 23,51 66,7 101,32 74,6 
 
72,86 3,5 0 27,61 B
+
SmB
+
Tr
 norm; 
21
lo
 
 
53,7 2,93 1,04 
  
    
     Lymph – lymphocytes  
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Table 3.  Comparison of clinical and immunological phenotypes  
Clinical Phenotypes 
Total lymph 
cells/μL 
CD19
+ 
% 
NK 
% 
CD3 
% 
CD4 
% 
CD4 
cells/μL 
Other autoimmune disease ns ns ns ns ns ns 
Autoimmnune Cytopenia ns ns ns ns ns ns 
Splenomegaly 0.0103 ns ns ns ns 0.0351 
Adenopathies ns ns ns ns ns ns 
Lymphoid proliferation ns ns ns ns ns ns 
Chronic diarrhea ns ns ns ns ns ns 
Bronchiectasis ns 0.0279 ns ns ns ns 
 
Significant differences regarding lymphocytes subpopulations are indicated for each clinical phenotype.  
Each value indicated in the table represents the p-value 
ns – not statistically significative; lymph- lymphocytes 
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Table 4 - Comparison between clinical and immunological phenotypes 
Clinical Phenotypes B-cells CD27
- 
% 
CD27
+
IgD
- 
% 
CD38
hi
IgM
hi 
% 
CD21
lo
CD38
lo 
% 
CD4  
T-cells 
CD45RA
+
CD27
+
 
% 
HLADR
+ 
% 
CD38
+
HLADR
+ 
% 
Other autoimmune 
disease 
 ns ns ns ns  ns ns ns 
Autoimmune cytopenia  ns ns ns 0.023  0.0078 0.0053 0.0063 
Splenomegaly  ns ns ns 0.0346  0.0132 0.0161 0.0149 
Adenopathies  ns ns ns ns  0.0004 <0.0001 0.0001 
Lymphoid Proliferation  ns ns ns 0.0491  ns 0.0123 0.0237 
Chronic Diarrhea  ns ns ns ns  ns ns ns 
Bronchiectasis  ns ns ns ns  ns ns ns 
 
Significant differences regarding lymphocytes subpopulations are indicated for each clinical phenotype.   
Each value indicated in the table represents the p-value. 
ns – not  statistically significative 
